公司概述
Anteris Technologies Global Corp. operates as a structural heart company focused on developing and commercializing minimally invasive medical devices designed to treat heart valve diseases. The firm specifically offers the DurAVR transcatheter heart valve system, a novel solution for the treatment of severe aortic stenosis, positioning itself within the specialized medical technology landscape. This entity functions within the Healthcare sector, specifically under the industry classification of Medical Instruments & Supplies, which implies a focus on high-precision equipment and patient care solutions. The company's scale is reflected in a market capitalization of $535.75M and an annual revenue of $1.91M, supported by a workforce of 174 employees. These valuation and revenue figures indicate a small-cap status with significant potential for expansion, though the current revenue level suggests the business is still in a growth or development phase relative to its market cap.
财务健康
The company reported revenue of $1.91M over the trailing twelve months, yet it posted a net income of $-94,144,000 and an EBITDA of $-92,233,000, revealing a substantial gap where operating costs and expenses far exceed the top-line revenue generation. This disparity indicates a highly aggressive cost structure or significant investment in R&D and commercialization that has not yet translated into profitability. The company's free cash flow stands at $-44,253,376, which signifies a negative cash position that limits immediate financial flexibility and suggests reliance on external capital sources to fund operations. Despite these challenges, the firm maintains $12.08M in cash against $2.28M in debt, providing a liquidity buffer, although the debt-to-equity ratio is listed as N/A due to the equity dynamics. The balance sheet appears leveraged in a traditional sense but is supported by a significant cash reserve relative to its debt load. Liquidity analysis is complicated by a current ratio of 0.73, which indicates that current assets are insufficient to cover current liabilities without relying on additional financing or asset liquidation. Return on Equity is reported at -301.9% and Return on Assets at -113.2%, metrics that reveal that management has not yet generated positive returns on the capital invested or assets accumulated.
估值评估
The valuation metrics present a complex picture with a P/E Ratio (TTM) listed as N/A due to the lack of positive earnings, while the Forward P/E is -5.68, and the Price to Book ratio is an anomalous -2755.00. The negative forward P/E and price-to-book figures imply that the market is pricing the stock based on future expectations or asset dilution scenarios rather than current earnings power. Additionally, the Price to Sales ratio is recorded at 280.06, and the EV/EBITDA is -5.70, suggesting that the market is willing to pay a high multiple of sales despite the company's lack of profitability, likely betting on the DurAVR system's commercial success. Regarding trading range, the 52-week high was $6.95 and the 52-week low was $2.34, providing a context for current market sentiment. The stock's volatility is characterized by a Beta of 0.55, which indicates that the share price is less volatile than the broader market, moving at approximately 45% of the market's amplitude.
Growth & Income
The company experienced a Revenue Growth (YoY) of -42.2%, while Earnings Growth (YoY) is N/A, indicating that the business is currently contracting in terms of top-line sales rather than expanding. The negative revenue growth implies that the company is either transitioning between product cycles, facing market headwinds, or is in a pre-revenue scaling phase where historical comparisons are not indicative of future potential. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute earnings to shareholders, meaning it reinvests its limited cash flow and raises capital to fund its operations and growth initiatives. The overall growth and income profile is characterized by significant revenue contraction and a lack of dividend income, reflecting a high-risk, high-potential investment profile typical of early-stage medical device developers.